Rheumatoid Arthritis News

Most patients with immune-mediated inflammatory diseases who had weakened responses to a standard vaccine series for COVID-19 mounted a serological response to a third dose, according to data published in Arthritis and Rheumatology.

Molecular signature response classifier-assisted rheumatoid arthritis treatment selection may improve real-world results in patients with rheumatoid arthritis, according to data published in Expert Opinion on Biological Therapy.

Although telehealth can be useful in treating patients with rheumatic diseases, diagnoses should be established in face-to-face visits, according to new EULAR points to consider.

Patients with autoimmune rheumatic diseases who are undergoing elective hip or knee arthroplasty should maintain their usual doses of methotrexate, leflunomide, hydroxychloroquine, sulfasalazine and apremilast , according to new guidelines.

The news that the Supreme Court may overturn Roe v. Wade sent a shockwave through all corners of the United States.

The 2022 EULAR recommendations for the management of rheumatoid arthritis are largely similar to the 2019 updates, with one point of emphasis being the importance of rapid glucocorticoid reduction and discontinuation.

Janus kinase inhibitors have delivered on some, but not all, of the promises that were expected of them upon approval in 2012, a speaker said at EULAR 2022 Congress.

CLEVELAND —In this video from the Medical Dermatology Therapy Update II meeting, Florian Rieder, MD, discusses how a medical home for inflammatory diseases could benefit patients.

CLEVELAND — In this video, M. Elaine Husni, MD, MPH, stressed the importance of taking into consideration the comorbidities of a patient with immune-mediated disease.

The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies.